Back to search results

Investigating OMT for COVID-19 Related Smell Loss

This study is looking into whether Osteopathic Manipulative Treatment (OMT) can help people recover their sense of smell after having COVID-19. Many people lose their sense of smell (anosmia) due to COVID-19, and there are few treatments available. OMT is a hands-on treatment that focuses on the body's natural ability to heal. In this study, OMT will involve specific techniques on the neck and nose area. You might be able to join if you are 18 or older, had a positive COVID-19 test, and have reported a loss of smell. The study will measure if OMT helps you get your sense of smell back, and how long that improvement lasts, for up to two weeks after treatment. The current status of this study is unclear.

Study design
This is an interventional study with a planned enrollment of 32 participants. It compares Osteopathic Manipulative Treatment (OMT) to a sham treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your ability to recover your sense of smell will be measured from enrollment until two weeks after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06766279

Investigating the Efficacy of OMT to Recover Olfactory Perception After COVID-19

Recruiting
NAAges 18+InterventionalTreatment
Burrell College of Health Sciences
~32 participants
Updated 2025-01-09 on ClinicalTrials.gov
What's tested:Osteopathic Manipulative TreatmentSham treatment

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Ability to Recover Sense of Smell after OMT
Measured over from enrollment until 2 weeks post treatment

Conditions

Anosmia

Explore related trials

Anosmia

Where it's being run

1 sites across 1 states
New Mexico1

Who to contact

Thomas P Eiting, Ph.D
[email protected]
575-674-2245
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Positive COVID-19 test or diagnoses
Self-reported deficiency in sense of smell

Exclusion

Age under 18 years
Pregnancy
Any findings on the osteopathic screening/evaluation that would hinder the effectiveness or increase the risk associated with OA decompression
Any medication that interferes with the sense of smell (intranasal zinc, intranasal antihistamines, intranasal corticosteroids)
Allergic rhinitis
Use of oral corticosteroids or antihistamines.

What this trial measures

  • Ability to Recover Sense of Smell after OMTfrom enrollment until 2 weeks post treatment

    Data from 32 COVID-19-positive individuals will be collected. This group will be divided into 2 groups of 16: one of these groups will be given the OMT intervention, and one will be given a sham intervention. The sample size of 16 per group comes about as follows. The main dependent variable measured for each person will be the number of odors identified out of a panel of 16 odors. This will be in the form of a multiple-forced-choice questionnaire: participants will be required to identify the odor from a selection of possible options. Upon treatment and re-testing, we will measure the number of odors identified again. Previous work (Whitcroft et al. 2016, Rhinology 54:368-373) that has looked at the effects of sodium citrate treatment on odor identification ability has shown a mean improvement of just over 2 points using this same identification test (for example, subjects able to correctly identify 14 odors posttreatment and just 12 odors pre-treatment).